Sherman S
Department of Respiratory Care, William Beaumont Hospital, Royal Oak, Michigan.
Postgrad Med. 1991 Jun;89(8):195-9, 202. doi: 10.1080/00325481.1991.11700963.
Pulmonary embolism continues to be an underdiagnosed, potentially fatal problem. Because clinical diagnosis of pulmonary embolism is notoriously inaccurate, clinical suspicions must always be confirmed with objective studies. Evaluation generally begins with ventilation-perfusion lung scanning. Further evaluation is usually unnecessary if the lung scan is interpreted as normal (diagnosis excluded) or high-probability (diagnosis accepted). However, if the lung scan is indeterminate (referring to all other interpretations), additional diagnostic studies are usually required. Newer trends in the management of pulmonary embolism and deep venous thrombosis include a more aggressive initial regimen of heparin; simultaneous administration of warfarin with heparin, resulting in a shorter duration of heparin therapy; use of the international normalized ratio to monitor warfarin therapy; and use of a less intense warfarin regimen. Adjusted-dose subcutaneous heparin therapy and low-intensity warfarin therapy are newer prophylactic techniques for patients at moderate to high risk for deep venous thrombosis.
肺栓塞仍然是一个诊断不足、潜在致命的问题。由于肺栓塞的临床诊断 notoriously 不准确,临床怀疑必须始终通过客观研究来证实。评估通常从通气-灌注肺扫描开始。如果肺扫描被解释为正常(排除诊断)或高概率(接受诊断),通常无需进一步评估。然而,如果肺扫描结果不确定(指所有其他解释),通常需要进行额外的诊断研究。肺栓塞和深静脉血栓形成管理的新趋势包括更积极的初始肝素治疗方案;华法林与肝素同时给药,从而缩短肝素治疗时间;使用国际标准化比值监测华法林治疗;以及使用强度较低的华法林方案。调整剂量的皮下肝素治疗和低强度华法林治疗是针对中度至高度深静脉血栓形成风险患者的较新预防技术。